Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
21 December 2020 | Story Eugene Seegers | Photo Sonia Small
Prof Fanie Snyman, retired Dean of the Faculty of Theology and Religion, is the first South African to publish a volume in the respected Tyndale Old Testament Commentaries series, which deals with the Bible books of Nahum, Habakkuk, and Zephaniah.

Against the backdrop of the Faculty of Theology and Religion’s 40th anniversary, Prof Fanie Snyman, retired Dean and research associate, has recently published a commentary in the Tyndale Old Testament Commentaries series based in Cambridge, England, on the prophetic books Nahum, Habakkuk, and Zephaniah of the Old Testament. What makes his book special is that Prof Snyman is the first and for the foreseeable future the only South African Old Testament scholar to be commissioned to publish in this distinguished commentary series. This commentary series is widely read and consulted in the English-speaking scholarly communities of Africa, Australia, Great Britain, New Zealand, the USA, and many European countries.

In a virtual ‘sit-down’ with Prof Fanie, he explained how a research volume of this type is usually compiled: It starts with a verse-by-verse analysis of the Bible books, looking at the literary aspects of how the passage was written as well as considering its historical, social, and cultural background. This is done to obtain a better overall understanding of the text. Secondly, a volume of commentary is not merely regurgitating knowledge that has already been generated. Prof Fanie says that “it must deliver new, fresh perspectives on the current state of research on these books. What can I contribute to the understanding of these writings?” To accomplish this, he had to pore over stacks of research on these prophetic works to be as current as possible with modern research.

First contributor from Africa

Dr David Firth, the series editor, says: “Over the nearly sixty-year history of the Tyndale Old Testament Commentaries, we have not previously had any contributors from Africa. That has now been put right with the release of Prof SD Snyman’s new volume on Nahum, Habakkuk, and Zephaniah. Prof Snyman has brought together his expertise on the prophetic literature of the Old Testament and theological awareness to present a fresh work on these often-neglected books. Through his careful attention to how these books functioned in their ancient setting and mastery of the secondary literature, he is also able to point to the enduring importance of each of these books for contemporary readers. As such, he has admirably fulfilled the brief for the series and produced a volume that will serve a new generation who come to these books.”

Prof Fanie affirms that the burning issues raised in each of these books regarding situations in ancient Israel often mimic comparable issues in our modern society. For example, he underscores how Nahum brings the misuse of political power to the fore, a current and topical point of contention. Prof Snyman says: “My aim was to create a vertical theological perspective of that historical situation against the backdrop of contemporary issues. I believe that these texts have a relevance for us and upon us today.”

Other international works

This book is the third one published internationally by Prof Snyman. In 2012, he published a book on the prophetic literature of the Old Testament together with a Dutch colleague in the USA. In 2015, he published a commentary on the book of Malachi in Europe. This book was awarded the UFS Book Prize for Distinguished Scholarship in 2017. 

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept